Bibliometric and Visualization Analysis of DprE1 Inhibitors to Combat Tuberculosis.

IF 4.7 2区医学 Q1 CHEMISTRY, MEDICINAL

Drug Design, Development and Therapy Pub Date : 2025-04-03 eCollection Date: 2025-01-01 DOI:10.2147/DDDT.S515049

Qingqing Wang, Huixiao Fu, Yining Zhang, Man Zhang, Jian Xu, Jian Fu

{"title":"Bibliometric and Visualization Analysis of DprE1 Inhibitors to Combat Tuberculosis.","authors":"Qingqing Wang, Huixiao Fu, Yining Zhang, Man Zhang, Jian Xu, Jian Fu","doi":"10.2147/DDDT.S515049","DOIUrl":null,"url":null,"abstract":"Background: Tuberculosis (TB) poses a serious threat to public health, particularly owing to the increase in multidrug-resistant tuberculosis (MDR-TB) and extremely drug-resistant tuberculosis (XDR-TB); thus, there is an imperative need for novel treatments to tackle this issue. Decaprenylphosphoryl-β-D-ribose 2'-epimerase (DprE1) is essential for mycobacterial cell wall integrity and viability. As no relevant bibliometric study has been reported, we performed bibliometric and visual analyses to depict the knowledge framework of research related to the involvement of DprE1 in TB.Methods: Relevant studies were sourced from the Web of Science Core Collection database. VOSviewer, CiteSpace, and bibliometrics (http://bibliometric.com/) were used to construct networks based on an analysis of journals, countries, funding, institutions, authors, references, and keywords.Results: A total of 184 publications were retrieved; the total citations were 3405 times and the mean citation was 17.28 per article. The annual number of publications on DprE1 in TB has shown a significantly increasing trend. The European Journal of Medicinal Chemistry is the most published journal, with 19 articles. Lu Yu and Bin Wang contributed the most prolific authors with 18 articles. Stratified by the number of publications, India was the most prolific country that cooperated closely with the USA, UK, Japan, and United Arab Emirates. Burstness analysis of references and keywords showed that the developing research trends in this field mainly woven around \"Mtb\", \"DprE1\" and \"inhibitors\" during the past years.Conclusion: A systematic bibliometric study indicates that DprE1 remains a focal point in the anti-TB domain. These results can serve as a data-driven reference for future research and offer precise insights into the development of anti-TB agents associated with DprE1. To the best of our knowledge, this study is the first to comprehensively investigate DprE1 in TB by means of bibliometric analysis.","PeriodicalId":11290,"journal":{"name":"Drug Design, Development and Therapy","volume":"19 ","pages":"2577-2596"},"PeriodicalIF":4.7000,"publicationDate":"2025-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11974558/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug Design, Development and Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/DDDT.S515049","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Tuberculosis (TB) poses a serious threat to public health, particularly owing to the increase in multidrug-resistant tuberculosis (MDR-TB) and extremely drug-resistant tuberculosis (XDR-TB); thus, there is an imperative need for novel treatments to tackle this issue. Decaprenylphosphoryl-β-D-ribose 2'-epimerase (DprE1) is essential for mycobacterial cell wall integrity and viability. As no relevant bibliometric study has been reported, we performed bibliometric and visual analyses to depict the knowledge framework of research related to the involvement of DprE1 in TB.

Methods: Relevant studies were sourced from the Web of Science Core Collection database. VOSviewer, CiteSpace, and bibliometrics (http://bibliometric.com/) were used to construct networks based on an analysis of journals, countries, funding, institutions, authors, references, and keywords.

Results: A total of 184 publications were retrieved; the total citations were 3405 times and the mean citation was 17.28 per article. The annual number of publications on DprE1 in TB has shown a significantly increasing trend. The European Journal of Medicinal Chemistry is the most published journal, with 19 articles. Lu Yu and Bin Wang contributed the most prolific authors with 18 articles. Stratified by the number of publications, India was the most prolific country that cooperated closely with the USA, UK, Japan, and United Arab Emirates. Burstness analysis of references and keywords showed that the developing research trends in this field mainly woven around "Mtb", "DprE1" and "inhibitors" during the past years.

Conclusion: A systematic bibliometric study indicates that DprE1 remains a focal point in the anti-TB domain. These results can serve as a data-driven reference for future research and offer precise insights into the development of anti-TB agents associated with DprE1. To the best of our knowledge, this study is the first to comprehensively investigate DprE1 in TB by means of bibliometric analysis.

查看原文本刊更多论文

抗结核DprE1抑制剂的文献计量学和可视化分析。

背景：结核病（TB）对公共卫生构成严重威胁，特别是由于耐多药结核病（MDR-TB）和极耐药结核病（XDR-TB）的增加；因此，迫切需要新的治疗方法来解决这个问题。decaprenylphospyl -β-D-ribose 2'- epimase （DprE1）对分枝杆菌细胞壁的完整性和生存能力至关重要。由于没有相关文献计量学研究的报道，我们进行了文献计量学和视觉分析来描述与DprE1参与结核病相关的研究知识框架。方法：相关研究来源于Web of Science Core Collection数据库。利用VOSviewer、CiteSpace和bibliomemetrics （http://bibliometric.com/）对期刊、国家、资助、机构、作者、参考文献和关键词进行分析，构建网络。结果：共检索文献184篇；总被引3405次，平均被引17.28次/篇。关于结核病DprE1的年度出版物数量呈显著增加趋势。《欧洲药物化学杂志》是发表文章最多的杂志，有19篇文章。作者最多的是鲁豫和王斌，共发表了18篇文章。按出版物数量分层，印度是与美国、英国、日本和阿拉伯联合酋长国密切合作的最多产的国家。对文献和关键词的突发性分析表明，近年来该领域的研究发展趋势主要围绕“Mtb”、“DprE1”和“inhibitors”展开。结论：系统的文献计量学研究表明，DprE1仍然是抗结核领域的一个焦点。这些结果可以作为未来研究的数据参考，并为开发与DprE1相关的抗结核药物提供精确的见解。据我们所知，本研究首次通过文献计量学分析全面研究了DprE1在结核病中的作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Drug Design, Development and Therapy CHEMISTRY, MEDICINAL-PHARMACOLOGY & PHARMACY

CiteScore

9.00

自引率

0.00%

发文量

382

审稿时长

>12 weeks

期刊介绍： Drug Design, Development and Therapy is an international, peer-reviewed, open access journal that spans the spectrum of drug design, discovery and development through to clinical applications. The journal is characterized by the rapid reporting of high-quality original research, reviews, expert opinions, commentary and clinical studies in all therapeutic areas. Specific topics covered by the journal include: Drug target identification and validation Phenotypic screening and target deconvolution Biochemical analyses of drug targets and their pathways New methods or relevant applications in molecular/drug design and computer-aided drug discovery* Design, synthesis, and biological evaluation of novel biologically active compounds (including diagnostics or chemical probes) Structural or molecular biological studies elucidating molecular recognition processes Fragment-based drug discovery Pharmaceutical/red biotechnology Isolation, structural characterization, (bio)synthesis, bioengineering and pharmacological evaluation of natural products** Distribution, pharmacokinetics and metabolic transformations of drugs or biologically active compounds in drug development Drug delivery and formulation (design and characterization of dosage forms, release mechanisms and in vivo testing) Preclinical development studies Translational animal models Mechanisms of action and signalling pathways Toxicology Gene therapy, cell therapy and immunotherapy Personalized medicine and pharmacogenomics Clinical drug evaluation Patient safety and sustained use of medicines.